Prostate Cancer

Niagara Falls, Ontario—Among men with prostate cancer and preexisting cardiovascular (CV) disease, the risk of CV events or CV-related death is cut in half when they receive androgen-deprivation therapy (ADT) with degarelix (Firmagon) instead of the luetinizing hormone–releasing hormone (LHRH) agonists goserelin (Zoladex) or leuprolide (Lupron), according to results of a new analysis presented at the 2013 Canadian Urological Association annual meeting.
Read Article

The management of patients with prostate cancer will be advanced by 2 new genetic tests—Oncotype DX prostate cancer test and Prolaris.
Read Article

A secondary analysis of a large study on intermittent versus continuous androgen-deprivation therapy (ADT) has confirmed the importance of aiming for very low testosterone levels in men after they are diagnosed with prostate cancer, according to new data presented at the 2013 Canadian Urological Association annual meeting.
Read Article

Evidence-based drug sequencing should form the basis of treatment for castration-resistant prostate cancer (CRPC), according to a new guideline from the American Urolo­gical Association (AUA) released at the 2013 AUA annual meeting.
Read Article

This is an abbreviated version of the original article that was recently published in American Health & Drug Benefits. 2013;6(1):15-24.
Read Article

Prostate cancer screening with prostate-specific antigen (PSA) tests should focus on men aged 55 to 69 years, the group that is the most likely to benefit from screening, according to a new clinical guideline issued by the American Urological Association (AUA) at its 2013 annual meeting.
Read Article

Boston, MA—Patients with prostate cancer reported significantly better sexual function for up to 2 years after radiation therapy when they took sildenafil (Viagra) on a daily basis during and after treatment, according to results of a placebo-controlled clinical trial.
Read Article

>Dutch researchers have peered into the minds and wallets of a group of men aged 55 to 75 years to determine what they are willing to trade for a reduced risk of prostate cancer–related death or to avoid unnecessary procedures and treatment.
Read Article


Feedback from their peers helped physicians refrain from ordering unnecessary tests for patients with newly diagnosed cancer, according to a recent study (Miller DC, et al. J Urol. 2011;186:844-849. Epub 2011 Jul 23).
Read Article

Page 7 of 8